Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.1752W HIGH $3.90
Volume
109.39 K
Value Traded
24.41 K
Short % Float
0.8%
-13.48%Week
-13.97%1 Month
+10.79%3 Month
+3.36%6 Month
-66.98%5 Year
-87.27%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
75.80 M
EPS (TTM)
-0.22
P/E Ratio
-
Ent. Value
50.38 M
Total Shares
49.23 M
Float Shares
46.70 M
Insiders
5.12%
Institutions
18.15%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
MNOV Catalyst Timeline
Dated clinical, regulatory and corporate events for MediciNova, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for MediciNova, Inc.
893Total events
6Upcoming
196Tier-1 (high impact)
2005 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutMN-001Clinical Data
Topline results from Phase 2 MN-001-NATG-202 trial of MN-001 (tipelukast) in NAFLD/hypertriglyceridemia with T2DM
hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM)source ↗
▲Secondary Endpoint DataMN-001Clinical Data
Statistically significant increases in HDL-C and HDL-P with MN-001 at Week 24
hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM)source ↗
▼Primary Endpoint MissedMN-001Clinical Data
Week 24 serum TG reduction with MN-001 vs placebo not statistically significant (p=0.113)
hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM)source ↗
▲Safety Data UpdateMN-001Clinical Data
MN-001 generally safe and well tolerated; no drug-related SAEs reported
hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM)source ↗
●Last Patient Last VisitMN-166Trial
Last patient, last visit completed in double-blind portion of COMBAT-ALS
Amyotrophic Lateral Sclerosis (ALS)source ↗
▲Enrollment CompleteibudilastTrial
Target enrollment of 200 patients achieved in SEANOBI-ALS expanded access program
amyotrophic lateral sclerosis (ALS)source ↗
◆Topline ReadoutMN-001Clinical Data
Topline data from Phase 2 MN-001-NATG-202 study in metabolic disease
metabolic diseasesource ↗
▲Last Patient Last VisitMN-001Trial
Last patient last visit completed in Phase 2 trial of MN-001 for hypertriglyceridemia and NAFLD with T2DM
hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM)source ↗
▲Enrollment MilestoneMN-166Trial
100 patients enrolled in SEANOBI EAP for MN-166 in ALS (50% of planned enrollment)
amyotrophic lateral sclerosis (ALS)source ↗
▲Patent GrantedMN-166IP / Competition
Notice of Allowance for U.S. patent covering ibudilast in combination with anti-PD-1 antibody for glioblastoma
glioblastomasource ↗
▲Patent GrantedMN-166IP / Competition
Notice of Allowance for patent covering MN-166 in combination with anti-PD-1 for glioblastoma
glioblastomasource ↗
▲Last Patient Last VisitMN-001Trial
Last patient last visit completed in Phase 2 trial of MN-001 (tipelukast) for hypertriglyceridemia and NAFLD with T2DM
hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM)source ↗
◆Topline ReadoutMN-001Clinical Data
Top-line data expected by summer 2026
hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to Type 2 diabetes (T2DM)source ↗
◆Oral PresentationPresentation
MediciNova to participate at 38th Annual ROTH Conference with one-on-one meetings
▲PublicationibudilastPresentation
Publication of MIF-CD74 study in Cancer Research
brain metastasissource ↗
▲Enrollment MilestoneMN-166Trial
100 patients enrolled in SEANOBI EAP (50% of planned 200 enrollment)
amyotrophic lateral sclerosis (ALS)source ↗
▲Enrollment CompleteMN-166Trial
Completed patient enrollment in OXTOX study evaluating MN-166 for prevention of chemotherapy-induced peripheral neuropathy
chemotherapy-induced peripheral neuropathysource ↗
●Poster PresentationMN-166Presentation
Poster presentation of COMBAT-ALS trial update and basic characteristics at 36th International Symposium on ALS/MND
Amyotrophic Lateral Sclerosis (ALS)source ↗
▲Management ChangeCorporate
Appointment of Dr. Christopher Breder as Clinical and Regulatory Advisor
▲Oral PresentationPresentation
MediciNova wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
▲Enrollment CompleteMN-001Trial
Patient enrollment completed in Phase 2 trial of MN-001 for hypertriglyceridemia and NAFLD due to T2DM
hypertriglyceridemia and non-alcoholic fatty liver disease (NAFLD) due to Type 2 diabetes (T2DM)source ↗
▲PublicationMN-001Presentation
Publication of research article on MN-002 enhancing cholesterol efflux in Journal of Atherosclerosis and Thrombosis
atherosclerosissource ↗
◆Enrollment UpdateMN-001Trial
Enrollment nearing completion in Phase 2 study of MN-001 in hypertriglyceridemia, Type 2 DM and NAFLD
hypertriglyceridemia, Type 2 diabetes, NAFLDsource ↗
▲Enrollment CompleteibudilastTrial
Patient enrollment completed in COMBAT-ALS Phase 2b/3 trial of MN-166 (ibudilast) for ALS
Amyotrophic Lateral Sclerosis (ALS)source ↗
▲Enrollment CompleteMN-166Trial
COMBAT-ALS Phase 2b/3 trial target enrollment achieved
Amyotrophic Lateral Sclerosis (ALS)source ↗
◆Enrollment UpdateMN-166Trial
EAP for MN-166 steadily enrolling patients
Amyotrophic Lateral Sclerosis (ALS)source ↗
◆Enrollment UpdateMN-001Trial
Phase 2 trial for MN-001 nearing completion of target enrollment
hypertriglyceridemia and fatty liver disease due to Type 2 diabetessource ↗
◆Oral PresentationPresentation
MediciNova to present at H.C. Wainwright 27th Annual Global Investment Conference
▲Enrollment CompleteibudilastTrial
Enrollment completed in COMBAT-ALS Phase 2b/3 trial
amyotrophic lateral sclerosis (ALS)source ↗
▲Enrollment CompleteMN-166Trial
Enrollment completed in COMBAT-ALS Phase 2b/3 trial of MN-166 (ibudilast) for ALS
Amyotrophic Lateral Sclerosis (ALS)source ↗
▲Enrollment UpdateMN-166Trial
COMBAT-ALS trial down to single digit required randomization
ALSsource ↗
▲Enrollment UpdateMN-001Trial
Seeking final two randomized subjects for Phase 2 trial
dyslipidemia and fatty liver disease due to type 2 diabetessource ↗
◆Enrollment CompleteMN-166Trial
Expect to complete patient assignments by June 2025
Amyotrophic Lateral Sclerosis (ALS)source ↗
◆R&D DayPresentation
MediciNova to participate in D. Boral Capital's Inaugural DBC Conference
▲First Patient DosedMN-166Trial
Plan to enroll first patient in SEA-NOBI-ALS study in 2Q 2025
ALSsource ↗
◆Trial InitiationMN-166Trial
NIH-funded Expanded Access Program trial set to begin next year
Amyotrophic Lateral Sclerosis (ALS)source ↗
◆Poster PresentationMN-166Presentation
Abstract accepted for poster presentation at 35th International Symposium on ALS/MND
Amyotrophic Lateral Sclerosis (ALS)source ↗
◆Oral PresentationMN-166Presentation
Presentation of study update and interim analysis at 35th International Symposium on ALS/MND
Amyotrophic Lateral Sclerosis (ALS)source ↗
▲Interim AnalysisMN-166Trial
Pre-defined interim analysis results presented; DSMB recommended trial continue
Amyotrophic Lateral Sclerosis (ALS)source ↗
●Enrollment UpdateMN-166Trial
Enrollment update: 228 enrolled, 193 randomized as of Dec 2024
ALSsource ↗
●Enrollment UpdateMN-001Trial
Enrollment update: 43 enrolled, 26 randomized as of Dec 2024
HyperTG + T2DM + NAFLDsource ↗
●Enrollment UpdateMN-166Trial
Enrollment update: 217 participants enrolled, 183 assigned as of Nov 15, 2024
Amyotrophic Lateral Sclerosis (ALS)source ↗
▲Patent GrantedMN-001IP / Competition
USPTO Notice of Allowance for patent covering MN-001 for decreasing triglyceride synthesis in the liver
triglyceride synthesis in the liversource ↗
Past FDA Catalysts and PDUFA Decisions
How MNOV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | MN-001 (tipelukast) | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C58 / 100
Pipeline Score
$734M
Pipeline Value
Undervalued
Valuation Signal
3
Drugs Scored
8.4x
rNPV / MCap
Top 9%
Micro Cap(rank 60 of 658)
Percentile Rank
MediciNova, Inc. carries a moderate pipeline score (58/100), with $2.9B risk-adjusted pipeline value, led by MN-001 in Diabetes Mellitus, Type 2 (Phase 2), across $124B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MN-001 Small moleculeNCT05464784 | Diabetes Mellitus, Type 2 | Phase 2 | ACTIVE NOT_RECRUITING | 40 | Dec 31, 2026 |
Clinical Trial Results
Readouts, endpoints and source filings for every MNOV program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| MN-001 (tipelukast) | hypertriglyceridemia and NAFLD in patients with type 2 diabetes | Phase 2 | 2026-09-28 | serum TG week 24: 45.8 mg/dL (21.78%); serum TG placebo week 24: 14.4 mg/dL (6.97%); mean difference week 24: 31.4 mg/dL; serum TG week 4: 54.7 mg/dL (26.05%); serum TG placebo week 4: 23.8 mg/dL (11.54%); mean difference week 4: 30.96 mg/dL; HDL C week 24: 3.3 mg/dL (8.39%); HDL C placebo week 24: -2.4 mg/dL (6.23%); HDL P week 24: 3.62 µmol/L (11.80%); HDL P placebo week 24: -0.9 µmol/L (3.00%); body weight week end: 4.91 lb (2.28%); body weight placebo week end: 0.55 lb (0.25%)Read More | MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| 3D Investment Partners Pte. Ltd.Formerly 10% Owner | Sell | -640,000 4,862,047 held | $2.70 | 09/25/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in MNOV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in MNOV for Q2 2026. | ||||
MNOV Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How MNOV ranks across every disease it competes in
Competitive Position is a premium feature
See how MNOV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialMNOV News
MNOV▼ -6%on this news
MediciNova to Participate in the Maxim Growth Summit
MediciNova, Inc. will participate in the Maxim Growth Summit from October 12-14, 2026, at the Hard Rock Hotel New York. Management will hold one-on-one meetings with interested investors. The company is advancing a late-stage pipeline of therapies for various diseases, including ALS and multiple sclerosis, while facing typical industry risks related to funding and clinical trials.
Read more →MNOV▼ -18.6%on this news· ran to -37% by day 3
MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova, Inc. announced positive topline results from its Phase 2 trial of MN-001 (tipelukast) for treating hypertriglyceridemia and NAFLD in patients with type 2 diabetes. The trial showed significant reductions in serum triglycerides and increases in HDL cholesterol. While liver fat and body weight showed trends toward improvement, further evaluation in larger studies is planned.
Read more →MNOV▼ -5.4%on this news· ran to -31% by day 3shared move
MediciNova Announces Completion of Last Patient, Last Visit in the Double-Blind Portion of the Phase 2b/3 COMBAT-ALS Trial of MN-166 (Ibudilast)
MediciNova has completed the last patient visit in the double-blind portion of the Phase 2b/3 COMBAT-ALS trial for MN-166 (ibudilast), aimed at treating ALS. The trial involved 234 participants and is expected to report topline results by the end of 2026. MN-166 has received Fast Track and Orphan Drug designations from the FDA.
Read more →MNOV▲ +7.4%on this news
MediciNova to Participate in Two Investor Conferences in September
MediciNova, Inc. will participate in two investor conferences in September 2026, highlighting its commitment to stakeholder engagement. The company anticipates reporting topline data from its Phase 2 MN-001-NATG-202 study by the end of Q3 and from the COMBAT-ALS study by year-end. MediciNova maintains a strong cash position to support its clinical development efforts.
Read more →MNOVMediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova has successfully achieved the target enrollment of 200 patients in the SEANOBI-ALS study, which evaluates MN-166 (ibudilast) for ALS patients. This milestone highlights the commitment of the ALS community and the support from the NIH. The study aims to provide access to this investigational drug for patients not eligible for clinical trials, with final follow-ups expected in early 2027.
Read more →MNOVMediciNova CEO Provides Shareholder Update
MediciNova, Inc. has provided a corporate update highlighting significant progress in its clinical trials, particularly the completion of the last patient visit in the Phase 2 trial for MN-001. The company anticipates initial data readout in Q3 2026. Additionally, MediciNova has strengthened its intellectual property portfolio and increased its equity research coverage, signaling growing investor interest.
Read more →MNOVMediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment
MediciNova, Inc. has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent covering the use of MN-166 in combination with anti-PD-1 immune checkpoint inhibitors for glioblastoma treatment. This patent is expected to enhance the company's intellectual property position and support ongoing evaluation of MN-166 in oncology. The patent claims include various treatment parameters, indicating a strategic approach to addressing glioblastoma.
Read more →MNOVMediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova, Inc. has announced the completion of the last patient last visit in its Phase 2 clinical trial, MN-001-NATG-202, for MN-001 (tipelukast). This trial evaluates the drug's effectiveness in treating hypertriglyceridemia and nonalcoholic fatty liver disease associated with type 2 diabetes. The study's co-primary endpoints focus on liver fat content and fasting serum triglycerides, with top-line data anticipated in Q3 2026.
Read more →MNOVNew Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation
MediciNova, Inc. announced a study revealing macrophage migration inhibitory factor (MIF) as a key target in brain metastasis. The research showed that ibudilast can inhibit MIF-CD74 signaling, potentially reversing immune reprogramming and reducing metastatic progression. The findings support a biomarker-guided clinical strategy for treating patients with brain metastases, with plans for collaboration on future clinical studies.
Read more →MNOV▲ +7.4%on this news
MediciNova to Participate at the 38th Annual ROTH Conference
MediciNova, Inc. will participate in the 38th Annual ROTH Conference from March 22-24, 2026. CEO Yuichi Iwaki and CBO David Crean will engage with investors through meetings to discuss company updates. MediciNova is advancing its clinical-stage therapies, including MN-166 and MN-001, targeting various diseases.
Read more →MNOVMediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
MediciNova has announced the enrollment of 100 patients in the SEANOBI Expanded-Access Program, which aims to evaluate MN-166 (ibudilast) in ALS patients. This milestone represents 50% of the planned enrollment of 200 patients across 12 sites in the U.S. The program is supported by a $22 million NIH grant and aims to provide treatment access while collecting valuable clinical data. The company also continues its COMBAT-ALS study, which is expected to yield top-line results by the end of 2026.
Read more →MNOVMediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
MediciNova, Inc. has announced the successful completion of patient enrollment for its Phase 2 OXTOX study, evaluating MN-166 (ibudilast) in preventing chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients. A total of 100 patients were randomized into two treatment arms across 11 clinical sites in Australia. Participants will continue treatment until disease progression or unacceptable side effects, with preliminary data expected in 2026. The study is part of broader late-stage clinical development of MN-166 for various serious conditions, including neurodegenerative diseases.
Read more →MNOVMediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
MediciNova has provided an update on its Phase 2b/3 clinical trial of MN-166 (ibudilast) for ALS, presented at the 36th International Symposium on ALS/MND. Despite challenges like slow enrollment during the COVID-19 pandemic, the company achieved its randomization goal and anticipates top-line data by the end of 2026. MN-166 has received Orphan Drug and Fast Track designations from the FDA.
Read more →MNOVMediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
MediciNova, Inc. has announced the appointment of Dr. Christopher D. Breder, MD, PhD, as its new Clinical and Regulatory Advisor. Dr. Breder is recognized for his extensive experience at the FDA and in the pharmaceutical industry, particularly in neurological therapies. His expertise will guide MediciNova's drug development programs and aid in the formation of a Scientific Advisory Board. The company is focused on advancing therapies for neurodegenerative diseases, with its lead asset, MN-166, currently in Phase 3 trials for ALS and DCM.
Read more →MNOVMediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
MediciNova, Inc. has been awarded the 'Contract Research and Development Innovation Award' at the Fifth Annual BioTech Breakthrough Awards for its work on MN-166, a drug candidate for ALS. The award underscores the company's commitment to developing therapies for neurological diseases. MediciNova is currently conducting a Phase 2/3 trial for MN-166, aiming to address significant unmet medical needs in ALS treatment.
Read more →MNOV▼ -5.3%on this newsshared move
MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)
MediciNova, Inc. has completed patient enrollment in its Phase 2 clinical trial, MN-001-NATG-202, which evaluates MN-001 (Tipelukast) for treating hypertriglyceridemia and non-alcoholic fatty liver disease associated with Type 2 diabetes. The trial is randomized, double-blind, and placebo-controlled, with top-line data expected in summer 2026. MN-001 is noted for its anti-inflammatory and anti-fibrotic properties.
Read more →MNOV▲ +39.5%on this newsshared move
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
MediciNova, Inc. announced the publication of a study in the Journal of Atherosclerosis and Thrombosis, highlighting the potential of MN-002, a metabolite of MN-001, in enhancing cholesterol efflux. This research indicates a novel therapeutic strategy for atherosclerosis. The company is also advancing clinical trials for MN-001 in various metabolic diseases.
Read more →MNOVMediciNova to Present at the LD Micro Main Event XIX Investor Conference
MediciNova, Inc. will present a corporate overview at the LD Micro Main Event XIX Investor Conference from October 19 to 22, 2025. CEO Yuichi Iwaki and CBO David Crean will lead the presentation, which will be available via live webcast. The company is developing a robust pipeline of therapies for various diseases, including ALS and MS.
Read more →MNOVMediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
MediciNova, Inc. has announced the completion of patient enrollment in its Phase 2b/3 clinical trial, COMBAT-ALS, for MN-166 (ibudilast) targeting ALS treatment. A total of 234 patients were enrolled across multiple sites in the U.S. and Canada. The trial aims to evaluate the drug's efficacy and safety, with top-line data expected by the end of 2026.
Read more →About MediciNova, Inc.
Headquarters4275 EXECUTIVE SQUARE, LA JOLLA, CA, 92037
BIOPHARMAWATCH ELITE PLUS
Trade the next MNOV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime